IO-108, a Fully Human Therapeutic Antibody Blocking the Myeloid Checkpoint LILRB2/ILT4, Promotes Innate and Adaptive Anti-Cancer Immunity in Preclinical Studies

Written By Lara Wilson

Ma J. et al. The American Association for Cancer Research (AACR) Annual Meeting 2022. April 8–13, 2022

Lara Wilson
Previous

A First-In-Human Phase 1 Trial of IO-108 as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Advanced Relapsed or Refractory Solid Tumors
Next

LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2–cFLIP–NF-κB signaling axis